| HOME >> BIOLOGY >> TECHNOLOGY |
- Joint fund-raising efforts will support collaborative work of this unique partnership
SEATTLE, Sept. 30 /PRNewswire-USNewswire/ -- The Swedish Neuroscience Institute (SNI) has joined forces with the Institute for Systems Biology (ISB) to fundraise for and collaborate on research they hope will lead to cures for diseases of the brain and nervous system. The new partnership brings together physicians, researchers and fundraisers from two of the most respected organizations in the Pacific Northwest.
Greg Foltz. M.D., SNI neurosurgeon and head of the recently opened Center for Advanced Brain Tumor Treatment at Swedish's Cherry Hill Campus, is jointly leading the project with Leroy Hood, M.D., Ph.D., ISB co-founder and president.
"This is the first time that such a large group of established researchers have been brought together from the fields of neurosurgery, neuropathology, systems biology, genomics and biostatistical analysis to address serious diseases affecting the brain, such as malignant brain tumors," said Dr. Foltz. "Also of significance is the fact that the SNI and ISB researchers are focused solely on developing early diagnostic tools and treatment solutions for human disease rather than theoretical pursuits."
The collaboration also brings to bear some of the most advanced research technologies that exist today.
"The SNI and ISB collaboration represents a powerful strategic partnership that joins the clinical expertise of Swedish with the systems biology, technology and computational expertise of ISB," said Dr. Hood. "This study will integrate many different types of biological information from these patients which may in time lead to a deep understanding of the kinds of brain tumors today that are inevitably fatal."
ISB has been a global leader in the development of systems biology and
the effort to identify organ-specific molecular 'fingerprints' in the blood
that could lead to the pre-symptomatic diagnosi
'/>"/>
| SOURCE Swedish Neuroscience Institute Copyright©2008 PR Newswire. All rights reserved |